Realizing Personalized Medicine Through Integrative Medicine, Science and Technology

July 10 - 15, 2016

Chairs Chih-Ming Ho and Edward McCabe

Vice Chairs Yen Yun and Edward J. Benz

The Hong Kong University of Science and Technology

Clear Water Bay, Kowloon

Hong Kong, CN

Venue and Travel Information

Hong Kong Advisory Board:Tony F. Chan, Kathryn Song Eng Cheah, Fanny M.C. Cheung, Arthur B. Ellis, Barry Halliwell, Nancy Ip, Jian Lu, Peter Mathieson, Alfonso Ngan, Paul Tam, Benjamin Wah, Henry Wong, Vivian Wing-Wah Yam, Kenneth Young, Albert Cheung-Hoi Yu

Conference Description

Patient response rates to chemotherapy are fairly low in cancer treatment, often due to human diversity and cancer heterogeneity. For almost all other diseases, the current population-averaged therapeutic approach is also hampered by the human diversity. Therefore, personalized medicine is necessary to improve treatment efficacy/response rate as well as safety by providing precisely tailored patient therapy. In this first GRC on "Personalized Medicine", we will review what we have achieved and how we should move forward.

Combinatorial treatment comprised of drugs, immunotherapy and radiations are commonly used in treating cancer, infectious disease and many other types of diseases for improving therapeutic outcomes and reduced drug resistance. Current methods are far from optimal. In addition, these combinatorial treatments will also vary from patient to patient.

Recent technology developments have enabled the precise determination of which medicines may be most effective for a group of patients with similar gene profiles. Guided by the patient's sequence database, the genotypic precision medicine (GPM) method can locate better targets for discovering new drugs and achieve much higher efficacy to improve response rates.

The major challenges of continually evolving set of genetic and epigenetic factors can render drug resistance. Based on the measured end-point phenotype of a specific patient, the emergence of phenotypic personalized medicine (PPM) can realize unprecedented levels of adaptability to the dynamic patient physical response and rapidly home in the optimized combinatorial therapy for individual personal level.

Current nano/micro technologies enable single cell sequencing, circulating tumor cell analysis, and ultrasensitive diagnosis. By converging GPM, PPM and nano/micro technologies, rationally designed optimal combinatorial therapy for a specific patient through integrative medicine, science and technology will be the next paradigm for personalized medicine.

Conference Program

Sunday
2:00 pm - 8:00 pm	Arrival and Check-in
6:00 pm	Dinner
7:30 pm - 7:40 pm	Welcome / Introductory Comments by GRC Site Staff
7:40 pm - 9:30 pm	Genotypic Precision Medicine and Phenotypic Personalized Medicine
	Discussion Leader: Bill Gahl (National Human Genome Research Institute, NIH, USA)
7:40 pm - 7:55 pm	Introduction by Discussion Leader
7:55 pm - 8:35 pm	Bruce Gelb (Icahn School of Medicine at Mount Sinai, USA) "Getting Personal: The Path from Congenital Heart Disease Genetics to Better Outcomes"
8:35 pm - 8:45 pm	Discussion
8:45 pm - 9:25 pm	Wee Joo Chng (Cancer Science Institute of Singapore, National University of Singapore, Singapore) and Edward Kai-Hua Chow (Cancer Science Institute of Singapore, National University of Singapore, Singapore) "Phenotypic Personalized Medicine in Multiple Myeloma"
9:25 pm - 9:30 pm	Discussion
Monday
7:30 am - 8:30 am	Breakfast
9:00 am - 12:30 pm	Personalized/Precision Medicine and Enabling Technologies
	Discussion Leader: Megan Frisk (Science Translational Medicine, USA)
9:00 am - 9:15 am	Introduction by Discussion Leader
9:15 am - 9:55 am	Steven Rosen (City of Hope National Medical Center, USA) "RNA Directed Therapy (8 Chloro-Adenosine), DNA Directed Therapy (Leflunomide) and Targeting Glucose Metabolism (Ritonavir Plus Metformin) – Bench to Bedside for AML and Myeloma"
9:55 am - 10:10 am	Discussion
10:10 am - 10:40 am	Group Photo / Coffee Break
10:40 am - 11:20 am	Dean Ho (Weintraub Center for Reconstructive Biotechnology, University of California, Los Angeles, USA) "Phenotypic Personalized Medicine: Actionable Individualization of Patient Therapy"
11:20 am - 11:35 am	Discussion
11:35 am - 12:15 pm	Geoffrey Ginsburg (Duke Center for Applied Genomics and Precision Medicine, USA) "Novel Paradigms for the Early Detection of Acute and Chronic Disease"
12:15 pm - 12:30 pm	Discussion
12:30 pm	Lunch
1:30 pm - 4:00 pm	Free Time
3:00 pm - 4:00 pm	Power Hour
	The GRC Power Hour is an optional informal gathering open to all meeting participants. It is designed to help address the challenges women face in science and support the professional growth of women in our communities by providing an open forum for discussion and mentoring.
	Organizer: Megan Frisk (Science Translational Medicine, USA)
4:00 pm - 6:00 pm	Poster Session
6:00 pm	Dinner
7:30 pm - 9:30 pm	Personalized Pediatric Medicine
	Discussion Leader: Katherine Janeway (Dana-Farber Cancer Institute, Harvard University, USA)
7:30 pm - 7:45 pm	Introduction by Discussion Leader
7:45 pm - 8:25 pm	Dennis Lo (Chinese University of Hong Kong, Hong Kong SAR China) "Unlocking Hidden Diagnostic Information from Plasma DNA"
8:25 pm - 8:40 pm	Discussion
8:40 pm - 9:20 pm	Charles Roberts (St. Jude Children's Research Hospital, USA) "SWI/SNF (BAF) Complex Mutations in Cancer: Mechanisms and Therapeutic Vulnerabilities"
9:20 pm - 9:30 pm	Discussion
Tuesday
7:30 am - 8:30 am	Breakfast
9:00 am - 12:30 pm	Intersection of Engineering and Medicine
	Discussion Leader: Hsing Jien Kung (National Health Research Institutes, Taiwan)
9:00 am - 9:15 am	Introduction by Discussion Leader
9:15 am - 10:00 am	Yanyi Huang (Peking University, China) "Connection Between the Heterogeneous Phenotypes and Genotypes at Single-Cell Level"
10:00 am - 10:15 am	Discussion
10:15 am - 10:30 am	Coffee Break
10:30 am - 11:15 am	Garry Nolan (Stanford University, USA) "Single Cell Deep Profiling of Cancer and Immunity"
11:15 am - 11:30 am	Discussion
11:30 am - 12:15 pm	Pasi Janne (Dana-Farber Cancer Institute, USA) "Strategies to Overcome Drug Resistance in EGFR Mutant Lung Cancer"
12:15 pm - 12:30 pm	Discussion
12:30 pm	Lunch
2:00 pm - 4:00 pm	Poster Session
4:00 pm - 6:00 pm	Individualized Medicine for Cancers
	Discussion Leader: Richard Weinshilboum (Mayo Medical School, Mayo Clinic, USA)
4:00 pm - 4:15 pm	Introduction by Discussion Leader
4:15 pm - 4:55 pm	Xianting Ding (Institute for Personalized Medicine, Shanghai Jiao Tong University, China) "In Vivo Drug Combination Optimization for Colon Cancer Treatment Through a Phenotype Personalized Medicine (PPM) Approach"
4:55 pm - 5:10 pm	Discussion
5:10 pm - 5:50 pm	Arjan Griffioen (VU University Medical Center, The Netherlands) and Patrycja Nowak-Sliwinska (University of Geneva, Switzerland) "Identification of Optimal Personalized Combination Therapy for Renal Cell Cancer"
5:50 pm - 6:00 pm	Discussion
6:00 pm	Dinner
Wednesday
7:30 am - 8:30 am	Breakfast
9:00 am - 12:30 pm	Genomics and Molecular Targets
	Discussion Leader: Garry Cutting (Johns Hopkins University, USA)
9:00 am - 9:15 am	Introduction by Discussion Leader
9:15 am - 9:55 am	Pan-Chyr Yang (National Taiwan University, Taiwan) "Precision Lung Cancer Therapy: EGFR-TK1 and Beyond"
9:55 am - 10:10 am	Discussion
10:10 am - 10:40 am	Coffee Break
10:40 am - 11:20 am	C. Thomas Caskey (Baylor College of Medicine, USA) "Metabolomics Adds Function to Genetic Precision Medicine"
11:20 am - 11:35 am	Discussion
11:35 am - 12:15 pm	William Mobley (University of California, San Diego, USA) "Defining Genes and Mechanisms Underlying Cognitive Deficits in Down Syndrome"
12:15 pm - 12:30 pm	Discussion
12:30 pm	Lunch
1:30 pm - 4:00 pm	Free Time
4:00 pm - 6:00 pm	Poster Session
6:00 pm	Dinner
7:00 pm - 7:30 pm	Business Meeting
	Nominations for the Next Vice Chair; Fill in Conference Evaluation Forms; Discuss Future Site and Scheduling Preferences; Election of the Next Vice Chair
7:30 pm - 9:30 pm	Personalized Therapies for Blood Disorders
	Discussion Leader: Qiang Tian (P4 Medicine Institute, USA)
7:30 pm - 7:45 pm	Introduction by Discussion Leader
7:45 pm - 8:25 pm	Andrew Feldman (Mayo Clinic Cancer Center, USA) "Individualizing Therapy in Lymphoma"
8:25 pm - 8:40 pm	Discussion
8:40 pm - 9:20 pm	Karl Tsim (Hong Kong University of Science and Technology, Hong Kong SAR China) and Yi-Kuen Lee (Hong Kong University of Science and Technology, Hong Kong SAR China) "Traditional Chinese Medicine: A Yin-Yang Balance of Personalized Medicine"
9:20 pm - 9:30 pm	Discussion
Thursday
7:30 am - 8:30 am	Breakfast
9:00 am - 12:30 pm	Personalized Immunotherapy
	Discussion Leader: Patrick Tan (Duke-NUS Medical School, Singapore)
9:00 am - 9:15 am	Introduction by Discussion Leader
9:15 am - 10:00 am	Yusuke Nakumura (Center for Personalized Therapeutics, University of Chicago, USA) "Cancer Precision Medicine and Neoantigen Vaccine Treatment"
10:00 am - 10:15 am	Discussion
10:15 am - 10:30 am	Coffee Break
10:30 am - 11:15 am	Lieping Chen (Yale University, USA) "The PD-1/PD-L1 Blockade: A New Class of Cancer Immunotherapy"
11:15 am - 11:30 am	Discussion
11:30 am - 12:15 pm	Ali Zarrinpar (David Geffen School of Medicine at UCLA, USA) "Patient-Specific Drug Interaction Mapping in Personalized Immunosuppression"
12:15 pm - 12:30 pm	Discussion
12:30 pm	Lunch
1:30 pm - 4:00 pm	Free Time
4:00 pm - 6:00 pm	Late-Breaking Topics
	Discussion Leader: Yiwu He (BGI, China)
4:00 pm - 4:20 pm	Introduction by Discussion Leader
4:20 pm - 4:50 pm	Gunaretnam Rajagopal (Janssen R&D, USA) and Zhen Gu (University of North Carolina at Chapel Hill, USA) "Integration of GPM. PPM and Enabling Technologies"
4:50 pm - 5:00 pm	Discussion
5:00 pm - 5:30 pm	Navaline Quach (Tecan, USA) and Julia Zhen (Thermo Fisher Scientific, USA) "Industrial Participation and Government Regulatory Process"
5:30 pm - 5:40 pm	Discussion
5:40 pm - 6:00 pm	General Discussion
6:00 pm	Dinner
Friday
7:30 am - 8:30 am	Breakfast
9:00 am	Departure